In 2023, significant strides were made in the Phase I clinical trial progress of the CCHFVaccine. Notably, this groundbreaking endeavor achieved multifaceted milestones, spanning from the successful vaccine production to rigorous toxicity clearance procedures. Our collaboration with the Swedish European Medicines Agency (EMA) proved pivotal, providing invaluable guidance and ensuring adherence to regulatory standards. The application was submitted in early 2024 and we are expecting a start of the trial in early Q2 2024.
As we apply for Phase 1 trial approval through the EMA, we remain committed to advancing scientific knowledge and translating it into tangible solutions for combating CCHF. Our journey towards vaccine development continues with unwavering determination and collaboration.